GSK 568893A

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameGSK 568893A

Drug Alias NameHuman papillomavirus (types 16, 18, 31, 45) L1 virus-like particle vaccine - GlaxoSmithKlineHuman papillomavirus quadrivalent (types 16, 18, 31, 45) recombinant vaccine - GlaxoSmithKlineTetravalent HPV L1 16/18/31/45 virus-like particle vaccine - GlaxoSmithKlineHuman papillomavirus (types 16, 18, 31, 45) L1 VLP vaccine - GlaxoSmithKlineGSK-568893A

ClassificationVaccines > Application > Therapeutic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsPapillomavirus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsN/A

Inactive IndicationsPapillomavirus Infections

Other Information

ATC CodeN/A